BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Nalee Kim, Jeong Il Yu, Hee Chul Park, Gyu Sang Yoo, Changhoon Choi, Jung Yong Hong, Ho Yeong Lim, Jeeyun Lee, Moon Seok Choi, Jung Eun Lee, Kyunga Kim. Incorporating sarcopenia and inflammation with radiation therapy in patients with hepatocellular carcinoma treated with nivolumabCancer Immunology, Immunotherapy 2020;  doi: 10.1007/s00262-020-02794-3
2
David Tai, Su Pin Choo, Valerie Chew. Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential BiomarkersCancers 2019; 11(12): 1926 doi: 10.3390/cancers11121926
3
Hailong Sheng, Yan Huang, Yazhi Xiao, Zhenru Zhu, Mengying Shen, Peitao Zhou, Zeqin Guo, Jian Wang, Hui Wang, Wencong Dai, Wanjun Zhang, Jingyuan Sun, Chuanhui Cao. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinomaJournal for ImmunoTherapy of Cancer 2020; 8(1): e000340 doi: 10.1136/jitc-2019-000340
4
Sunmin Park, Won Sup Yoon, Mi Hee Jang, Chai Hong Rim. Clinical efficacy of external beam radiotherapy complementing incomplete transarterial chemoembolization for hepatocellular carcinomaInternational Journal of Radiation Biology 2020; : 1 doi: 10.1080/09553002.2020.1830316
5
Ann-Lii Cheng, Chiun Hsu, Stephen L. Chan, Su-Pin Choo, Masatoshi Kudo. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinomaJournal of Hepatology 2020; 72(2): 307 doi: 10.1016/j.jhep.2019.09.025
6
Yifei Dai, Weijie Qiang, Kequan Lin, Yu Gui, Xun Lan, Dong Wang. An immune-related gene signature for predicting survival and immunotherapy efficacy in hepatocellular carcinomaCancer Immunology, Immunotherapy 2020;  doi: 10.1007/s00262-020-02743-0
7
Vincenzo Quagliariello, Margherita Passariello, Domenica Rea, Antonio Barbieri, Martina Iovine, Annamaria Bonelli, Antonietta Caronna, Gerardo Botti, Claudia De Lorenzo, Nicola Maurea. Evidences of CTLA-4 and PD-1 Blocking Agents-Induced Cardiotoxicity in Cellular and Preclinical ModelsJournal of Personalized Medicine 2020; 10(4): 179 doi: 10.3390/jpm10040179
8
Wenzhe Yin, Jun Xu, Chao Li, Xiankui Dai, Tong Wu, Jifeng Wen. Plantamajoside inhibits the proliferation and epithelial‐to‐mesenchymal transition in hepatocellular carcinoma cells via modulating hypoxia‐inducible factor‐1α‐dependent gene expressionCell Biology International 2020; 44(8): 1616 doi: 10.1002/cbin.11354
9
Thomas Helmberger. The evolution of interventional oncology in the 21st centuryThe British Journal of Radiology 2020; 93(1113): 20200112 doi: 10.1259/bjr.20200112
10
Changhoon Choi, Yeonwoo Cho, Arang Son, Sung-Won Shin, Yeon-Ju Lee, Hee Chul Park. Therapeutic Potential of (−)-Agelamide D, a Diterpene Alkaloid from the Marine Sponge Agelas sp., as a Natural Radiosensitizer in Hepatocellular Carcinoma ModelsMarine Drugs 2020; 18(10): 500 doi: 10.3390/md18100500
11
Edo Kon, Itai Benhar. Immune checkpoint inhibitor combinations: Current efforts and important aspects for successDrug Resistance Updates 2019; 45: 13 doi: 10.1016/j.drup.2019.07.004
12
Hye Won Lee, Kyung Joo Cho, Jun Yong Park. Current Status and Future Direction of Immunotherapy in Hepatocellular Carcinoma: What Do the Data Suggest?Immune Network 2020; 20(1) doi: 10.4110/in.2020.20.e11
13
Li-Bin Xu, Zhen-Guo Zhao, Song-Feng Xu, Xin-Xin Zhang, Ting Liu, Chang-You Jing, Shu-Guang Zhang, Sheng-Ji Yu. The landscape of gene mutations and clinical significance of tumor mutation burden in patients with soft tissue sarcoma who underwent surgical resection and received conventional adjuvant therapyThe International Journal of Biological Markers 2020; 35(3): 14 doi: 10.1177/1724600820925095
14
Magalie Dosset, Elodie Lauret-Marie Joseph, Thaiz Rivera Vargas, Lionel Apetoh. Modulation of Determinant Factors to Improve Therapeutic Combinations with Immune Checkpoint InhibitorsCells 2020; 9(7): 1727 doi: 10.3390/cells9071727